{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["125"],"submitter":["Chu X"],"pubmed_abstract":["Background
Tocilizumab, an interleukin-6 receptor inhibitor, is a promising cytoprotective agent selected by the Stroke Preclinical Assessment Network. It showed a protective effect on infarct volume and functional outcomes in animal stroke models.Methods
In this investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial, patients with acute ischaemic stroke undergoing EVT were recruited. Eligible patients were randomly assigned (1:1) to receive tocilizumab or placebo treatment. Both patients and investigators were blinded to the treatment assignments. A single dose of tocilizumab (240 mg) or placebo was administered intravenously as soon as possible within 24 h after stroke onset and within 1 h after randomisation. The primary efficacy outcome "],"journal":["EBioMedicine"],"pagination":["106167"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12917384"],"repository":["biostudies-literature"],"pubmed_title":["Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial."],"pmcid":["PMC12917384"],"pubmed_authors":["Wang A","Wang B","Dong X","Wu C","Wang H","Zhang S","Dong Q","Zhang Q","Wang L","Xiong Y","Wang N","Gu H","Liebeskind DS","Shang L","Kang M","Wen C","Su Y","Chen S","Wang Y","Sun J","Yuan S","Li H","Li J","Li C","Chen J","Baron JC","Feng X","Feng Y","Chen L","Chu X","Sun W","Li R","Gao Q","Yang Y","Li S","Fisher M","Lu H","Xu S","Feng W","Yang Q","Yang S","Lan J","Liu H","Yu L","Liu J","Cao J","Zhao W","Ma Z","Bo H","Wei W","Niu X","Liu Y","Ding Y","Zhou C","Jia X","Li A","Yin Y","Cheng F","IRIS investigators","Ji X","Ma H","Liu B","Liesz A","Han J","Fang M","Ye H","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial.","description":"Background
Tocilizumab, an interleukin-6 receptor inhibitor, is a promising cytoprotective agent selected by the Stroke Preclinical Assessment Network. It showed a protective effect on infarct volume and functional outcomes in animal stroke models.Methods
In this investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial, patients with acute ischaemic stroke undergoing EVT were recruited. Eligible patients were randomly assigned (1:1) to receive tocilizumab or placebo treatment. Both patients and investigators were blinded to the treatment assignments. A single dose of tocilizumab (240 mg) or placebo was administered intravenously as soon as possible within 24 h after stroke onset and within 1 h after randomisation. The primary efficacy outcome ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T09:58:43.408Z","creation":"2026-07-09T10:49:48.276Z"},"accession":"S-EPMC12917384","cross_references":{"pubmed":["41687453"],"doi":["10.1016/j.ebiom.2026.106167"]}}